Petitprez, Florent
de Reyniès, Aurélien
Keung, Emily Z.
Chen, Tom Wei-Wu
Sun, Cheng-Ming
Calderaro, Julien
Jeng, Yung-Ming
Hsiao, Li-Ping
Lacroix, Laetitia
Bougoüin, Antoine
Moreira, Marco
Lacroix, Guillaume
Natario, Ivo
Adam, Julien
Lucchesi, Carlo
Laizet, Yec′han
Toulmonde, Maud
Burgess, Melissa A.
Bolejack, Vanessa
Reinke, Denise
Wani, Khalid M.
Wang, Wei-Lien
Lazar, Alexander J.
Roland, Christina L.
Wargo, Jennifer A.
Italiano, Antoine
Sautès-Fridman, Catherine
Tawbi, Hussein A.
Fridman, Wolf H.
Article History
Received: 29 June 2018
Accepted: 26 November 2019
First Online: 15 January 2020
Competing interests
: W.H.F. is a consultant for AstraZeneca, Novartis, Servier and Pierre Fabre. A.I. serves in the advisory board of Bayer, Daiichy, Epizyme, Lilly, Novartis, Roche and Springworks, and received research funding from Astra Zeneca, Bayer, Chugai, Merck, MSD, Novartis and Pharmamar. J.A. is a consultant for AstraZeneca, Bayer, BMS, MSD and Roche and received research funding from MSD, Pfizer and Pierre Fabre. J.A.W. participated on advisory boards for Merck, BMS, Novartis, Astra Zeneca, Roche Genentech and Illumina. M.A.B. is a consultant for EMD Serono, Immune Design, Eisai. H.A.T. serves on advisory boards and receives consulting fees from BMS, Merck and Genentech, and received research funding from BMS, Merck, Celgene, GSK, and Genentech. T.W.-W.C. participated in advisory boards for Eisai and Lilly and received research funds from Eisai. C.L.R. received research funding from BMS. The other authors declare no conflict of interest.